Skip to main content
. 2021 Apr 30;7(18):eabf7390. doi: 10.1126/sciadv.abf7390

Fig. 3. Improved cationic LPH:siRNA extravasation, penetration, and cellular uptake in the GL261 glioma mouse tumors using MB-FUS.

Fig. 3

(A) In vivo experimental protocol for LPH:siRNA delivery in a GL261 glioma mice tumor model. LPH:siRNA distribution is analyzed at 8 hours after nanoparticle administration. (B) Representative fluorescent microscopy data of LPH:siRNA extravasation and penetration in tumor at 8 hours after LPH:siRNA administration. (C) Quantification of the LPH extravasation in tumor with and without FUS at 8 hours after treatment (13.7-fold, P = 0.044). (D) Quantification of the siRNA penetration in tumor with and without FUS at 8 hours after treatment (5.4-fold, P = 0.0045). (E) Quantification of siRNA delivery to cancer cells with and without FUS at 8 hours after treatment (9.5-fold, P = 0.0364). (F) Quantification of the ratio of LPH (blue) and Cy5-siRNA (red) delivery to cancer cells to total cell uptake at 8 hours after FUS treatment. (G) Representative fluorescent microscopy data of LPH:Cy5-siRNA cellular uptake in tumor at 8 hours after LPH:siRNA administration. Green arrows show the LPH:siRNA uptake by cancer cells, and white arrows show the LPH:siRNA uptake by brain cells. Plots show means ± SEM (N = 3). P values were determined by unpaired t tests. *P ≤ 0.05 and **P ≤ 0.01